Stocks Health care PVLA
NASDAQ · Health carePalvella Therapeutics, Inc. (PVLA)
It posted a net loss of $75M. At September 30, 2026 it held $193.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about Palvella Therapeutics, Inc.
- Net worth
- Palvella Therapeutics, Inc. has a market value (market cap) of $2.4B at the latest share price, and shareholders' equity of $197.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2023 revenue was $42.8M (+65.3% year on year), with net income of $18.7M.
- Cash flow
- In fiscal 2025 operations used $25M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Palvella Therapeutics, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Palvella Therapeutics, Inc. does
Palvella Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PVLA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$41.7M | -$3.71 | n/a |
| 2024 | n/a | -$17.4M | -$7.83 | n/a |
| 2023 | $42.8M | $18.7M | $2.17 | -$13.9M |
| 2022 | $25.9M | -$33.3M | -$0.45 | -$61M |
| 2021 | $31.4M | -$45.7M | -$0.71 | -$8.6M |
| 2020 | $29.3M | -$37.2M | -$0.68 | -$48.6M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Palvella Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026
- November 5, 2026
- October 28, 2026Passive stake changed SCHEDULE 13G/A
- October 28, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 4, 2026
- August 4, 2026
- August 4, 2026
- August 3, 2026Passive stake (5% or more) SCHEDULE 13G
Insider trades
What the people running Palvella Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $9.6M worth of shares in the last 90 days and bought none on the open market. Most of the selling (99%) was pre-planned under Rule 10b5-1 trading plans.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| October 21, 2026 | Goin KathleenChief Operating Officer | Exercised options | 2,165 | $15.5K |
| October 21, 2026 | Goin KathleenChief Operating Officer | Exercised options | 2,148 | $19.5K |
| October 21, 2026 | Goin KathleenChief Operating Officer | Soldpre-planned (10b5-1) | 2,043 | $252.6K |
| October 21, 2026 | Goin KathleenChief Operating Officer | Soldpre-planned (10b5-1) | 1,663 | $208.1K |
| October 21, 2026 | Goin KathleenChief Operating Officer | Soldpre-planned (10b5-1) | 607 | $76.6K |
| October 14, 2026 | Jenkins George MDirector | Soldpre-planned (10b5-1) | 476 | $57.7K |
| October 14, 2026 | Jenkins George MDirector | Soldpre-planned (10b5-1) | 2,072 | $254.1K |
| October 14, 2026 | Jenkins George MDirector | Soldpre-planned (10b5-1) | 2,604 | $321K |
Who owns PVLA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Kaupinen Wes13D, may seek influence with 4 related filers | 14.6% | December 20, 2024 |
| Suvretta Capital Management, LLC13G, passive with 2 related filers | 7.4% | November 13, 2025 |
| Jennison Associates LLC13G, passive | 6.7% | August 3, 2026 |
| Frazier Life Sciences Public Fund, L.P.13G, passive with 13 related filers | 6% | February 13, 2026 |
| First Light Asset Management, LLC13G, passive with 1 related filers | 5.34% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 197 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Montanova Capital, LLC | 1,135,406 | -18,090 |
| Jennison Associates LLC | 960,619 | +320,008 |
| BlackRock, Inc. | 918,357 | +231,504 |
| Frazier Life Sciences Management, L.P. | 882,400 | 0 |
| First Light Asset Management, LLC | 771,901 | -208,857 |
| Bvf Inc | 672,789 | -288,200 |
| State Street Corp | 653,172 | +194,173 |
| Vanguard Capital Management LLC | 513,794 | +36,500 |
| Frontier Capital Management Co LLC | 478,833 | +104,798 |
| Federated Hermes, Inc. | 433,015 | 0 |
| Woodline Partners LP | 317,517 | 0 |
| Orbimed Advisors LLC | 292,360 | +157,760 |
| Geode Capital Management, LLC | 276,164 | +70,555 |
| Siren, L.L.C. | 257,485 | 0 |
| Primecap Management Co | 256,182 | +61,152 |
| Eventide Asset Management, LLC | 231,484 | -1,764 |
| Emerald Advisers, LLC | 229,486 | +67,986 |
| Fmr LLC | 214,841 | -967 |
| Alliancebernstein L.P. | 253,168 | -9,667 |
| Mpm Bioimpact LLC | 204,027 | -2,377 |
Insiders
4 insiders reported holding 181,678 shares in total, about $30.7M at the last price.
| Holder | Shares |
|---|---|
| Jenkins George MDirector | 132,616 |
| Heron Elaine JDirector | 47,812 |
| Korenberg Matthew ECFO, Treasurer | 1,000 |
| Kiritsy Christopher PDirector | 250 |
Questions about PVLA
What does Palvella Therapeutics, Inc. do?
Palvella Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as PVLA. Its shares trade on NASDAQ under the ticker PVLA.
What is Palvella Therapeutics, Inc.'s net worth?
Palvella Therapeutics, Inc. has a market value (market cap) of $2.4B at the latest share price, and shareholders' equity of $197.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Palvella Therapeutics, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $75M.
When did Palvella Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is Palvella Therapeutics, Inc.'s next earnings report?
Palvella Therapeutics, Inc.'s next report is expected around February 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PVLA with
Follow PVLA
Get an email when Palvella Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Palvella Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.